Additionally, with the advent of low-cost generic statins and the evidence showing their safety, it may actually be feasible and more cost-effective to treat individuals over a certain age threshold rather than stratifying future CHD risk by LDL-C, FRS, PCE, CAC, or CRP levels [18,19]. Here, CRP is linked to coronary artery disorder.